Comprehensive Outcomes for After Cancer Health (COACH)

December 6, 2024 updated by: Pack Health

Comprehensive Outcomes for After Cancer Health (COACH): the Feasibility and Impact of an MHealth Augmented Coaching Program for Self-Management in Cancer Survivors

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group will be monitored via patient reported and clinical outcomes as well as wearable data for the first 6 months followed by 6 months of digital health coaching. Both groups will collect fecal microbiome samples at enrollment and month 6. The study aims to explore if and how digital health coaching may be used to enhance outcomes for individuals following completion of primary cancer therapy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Background: There are an estimated 16.9 million cancer survivors in the United States, accounting for approximately 5% of the entire US population, and this number is anticipated to increase by 31% over the next 10 years to include 22.2 million individuals.1 Due to advances in therapy individuals with cancer are experiencing increased overall survival that is often accompanied by the management of cancer as a chronic condition.2 As such many individuals require maintenance therapies that extend for months or years beyond the completion of primary therapy with surgery, radiation, and/or pharmacologic therapies. Chronic management of cancer care may include both long-term maintenance therapy as well as the management of treatment-related sequelae, the majority of which occurs beyond the clinical setting. Supportive care needs include symptom support, general wellness, and a focus on the importance of adherence to treatment and follow-up, all of which may influence quality and quantity of life. Accordingly, there is a critical and growing need for comprehensive, accessible platforms to support survivor self-management of symptoms and general wellness (including physical, functional, and psychosocial well-being and healthcare adherence). There is furthermore a critical knowledge gap on the correlation between individual symptoms and wellness on novel biomarkers, specifically intestinal (gut) microbiome. Gut microbiome regulates critical physiological processes-digestion, mood, and overall immune health, but to date studies have focused on dysbiosis during cancer treatment. The investigators seek to explore dynamics of gut microbiota after cancer treatment and understand how health behavioral changes prompted by health coaching to modulate symptoms and physical/ psychosocial well-being may also positively influence the restoration of gut flora.

Aims: The objective of this randomized, wait-list control study is to assess the effect of a 6-month digital health coaching program in cancer survivors within 1 year of primary treatment and longitudinally measure its impact on multifaceted health outcomes. The investigators aim to: 1) Primarily, assess the feasibility, acceptability, and effect of digital health coaching on participants' health self-efficacy; 2) Secondarily, characterize associations between participant symptoms, physical/psychosocial well-being, and health self-management and gut microbiota changes; and 3) Explore patient-generated health data outcomes among participants (patient-reported [PROs] and wearable biometrics outcomes).

Methods: The proposed study will utilize a randomized-wait list control design to enroll up to 625 individuals with diverse tumor types who have completed primary treatment and are within 1 year of diagnosis. Each of up to 8 collaborating sites will enroll up to 100 participants. Participants will be enrolled in a 6-month digital health coaching program that combines person-to-person calls once weekly, accompanied by up to 4 digital nudges of evidence-based content via text, email and/or mobile application, based on the participant's preference. Content will focus on key topics designed to optimize survivorship outcomes, including management of late and long-term effects of therapy, diet and exercise, fatigue, financial toxicity, and other associated symptoms (e.g., sleep disturbance, depression), medication adherence, surveillance, and managing anxiety and fear of cancer recurrence. The program emphasizes targeting modifiable behaviors that can improve quality of life and health outcomes, including progression-free and overall survival. Those randomized to the intervention group will receive the 6-month coaching intervention up front followed by 6 months of on-going clinical, patient reported, activity, and microbiome data collection. Those randomized to the control will receive 6-months of clinical, patient reported, activity, and microbiome data collection, after which they will be randomized to the digital health coaching intervention.

Outcome Measures: All participants will be followed for 12-months during which time they will be provided with Fitbit devices to track engagement in physical activity. Microbiome samples will be collected at enrollment and 6 months to explore biomarkers of inflammation, which will be analyzed to examine associations between microbiota signatures and engagement in physical activity and PROs. Genomic bacterial DNA will be extracted and analyzed for any taxonomic changes in the microbiota diversity and composition with 16s rRNA sequencing. Microbiome analysis will be conducted in partnership with The National Institute of Nursing Research (NINR). PROs will be collected at baseline and months 3, 6, 9, and 12 to track progress during and following the program and to provide insights into the experience of quality of life, symptom burden, mental health, cognitive function, sleep quality, sexual health, and financial toxicity.

Rationale: This program seeks to address survivors' total well-being, including co-morbid conditions, psychosocial wellness, and healthy lifestyle behaviors, to enhance outcomes for individuals who have completed primary therapy for a cancer diagnosis. The approach is innovative in exploring how digital health coaching may be used to support the holistic needs of cancer survivors beyond the clinical care setting. The robust collection of patient-reported, wearable, biomarker, and clinical data, as well as qualitative data related to patient priorities, concerns and challenges in the context of Health Coaching, will allow for triangulation of data to comprehensively inform the experience of individuals following primary therapy as they manage their health in the community setting.

Study Type

Interventional

Enrollment (Estimated)

625

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Florida
      • Gainesville, Florida, United States, 32610
        • Active, not recruiting
        • The University of Florida
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
    • Nebraska
      • Omaha, Nebraska, United States, 68106
        • Active, not recruiting
        • University of Nebraska Medical Center
    • New York
      • New York, New York, United States, 10065
        • Not yet recruiting
        • Memorial Sloan Kettering Cancer Center
        • Contact:
        • Contact:
          • Kristen L Fessele, PhD
    • Ohio
      • Columbus, Ohio, United States, 43210
        • Active, not recruiting
        • The Ohio State University Wexner Medical Center
    • Texas
      • Houston, Texas, United States, 77030
      • Houston, Texas, United States, 77030
        • Not yet recruiting
        • The University of Texas MD Anderson Cancer Center
        • Contact:
          • Meagan Whisenant, PhD
        • Contact:
          • Debu Tripathy, MD
        • Contact:
          • Abbey Kaler, MSN
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Have primary diagnosis of cancer;

  2. Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer

    1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy
    2. For individuals with metastatic cancer, individuals may be included provided they completed primary therapy for a de novo diagnosis of metastatic disease within the last year, are within one year of completion of initial therapy for their primary cancer diagnosis for which disease progression has occurred, or who are within one year of receiving treatment for metastatic disease (including individuals currently receiving treatment).
  3. Are aged 18 years and older;
  4. Can read and consent to participate in the trial;
  5. Can read and speak English;
  6. Can complete study follow-up at pre-specified intervals;
  7. Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data.

Exclusion Criteria:

  1. Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments;
  2. Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider)
  3. Have a life expectancy of <6 months, and/or
  4. Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes.

Healthy Volunteers must:

  1. Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older.
  2. Must reside in the same dwelling as the patient participant
  3. Can read and consent to participate in the trial;
  4. Can read and speak English;
  5. Can complete study follow-up at pre-specified intervals;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
Behavioral: Digital Health Coaching Program
Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
Device: Fitbit
Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Other: Wait List Control Group
In addition to standard of care services, individuals in the wait list control will be monitored via the collection of PRO, clinical, and wearable data for the first 6 months, along with fecal microbiome collection at study enrollment baseline (study enrollment) and month 6. At month 6 these individuals will be enrolled into the 6-month digital health coaching program, during which clinical, PRO and wearable data will continue to be collected. At the completion of the 6-month coaching these individuals will come off study and will not receive additional follow-up.
Behavioral: Digital Health Coaching Program
Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
Device: Fitbit
Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
No Intervention: Household Healthy Participants
A cohort of consisting of adults without a cancer diagnosis residing in the same residence as participants, will be consented to collect fecal microbiome specimens to serve as a control for potential regional variation in microbiome dysbiosis. Up to 25 healthy controls will be enrolled per 100 participants at each study site. At sites enrolling fewer than 100 participants, an n up to 25% of the total patient enrollment sample will be approached for enrollment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of coaching intervention
Time Frame: At 6 months following the start of the coaching intervention
A 3-item questionnaire evaluating the following: 1) The digital health coaching program is easy to participate in; 2) the digital health coaching program is useful to me; 3) the digital health coaching program is relevant to my survivorship experience. Responses will be provided on a 10-point Likert scale ranging from 1 (Not at all) to 10 (Very Much).
At 6 months following the start of the coaching intervention
Feasibility of coaching intervention
Time Frame: At 6 months following the start of the coaching intervention
A retention rate greater than or equal to 70%. Retention is defined as individuals who agree to participate in the digital health coaching program completing the 6-months of engagement post-enrollment.
At 6 months following the start of the coaching intervention
Change in Self-Efficacy for Managing Chronic Disease
Time Frame: Change in baseline perception of self-efficacy at 12 months
A 6-item instrument measures how confident an individual is in engaging in certain health management activities. Responses are provided on a 10-point scale ranging from 1(not at all confident) to 10 (totally confident). A mean score is calculated for the instrument with a higher score indicating higher self-efficacy.
Change in baseline perception of self-efficacy at 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) Short Form v2.0 Physical Function 10a
Time Frame: Change in baseline perception of physical function at 12 months
A 12-item instrument assessing respondents' abilities to perform physical tasks and activities of daily living. Items are scored on 5-point Likert scales, with higher scores indicating higher physical functioning.
Change in baseline perception of physical function at 12 months
Change in Quality of Life as measured by The Functional Assessment of Cancer Therapy - General v4 (FACT-G)
Time Frame: Change in baseline perception of quality of life at 12 months
A 27-item instrument using a 5-point Likert scale ranging from 0 (not at all) to 4 (very much) to measure QoL across four dimensions: physical, social/family, emotional and functional. The FACT-G, validated for use with individuals with diverse cancer types, in addition to condition specific items as available by tumor type.
Change in baseline perception of quality of life at 12 months
Change in Anxiety as measured by the PROMIS Anxiety Short Form 8a
Time Frame: Change in baseline perception of anxiety at 12 months
An 8-item instrument measuring indicators of anxiety with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater anxiety.
Change in baseline perception of anxiety at 12 months
Change in Depression as measured by the PROMIS Depression Short Form 8a
Time Frame: Change in baseline perception of depression at 12 months
An 8-item instrument measuring indicators of depression with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater depression.
Change in baseline perception of depression at 12 months
Change in Cognitive Function as measured by the PROMIS Cognitive Function Short Form 8a
Time Frame: Change in baseline perception of cognitive impairment at 12 months
An 8-item instrument measuring indicators of cognitive function with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater cognitive impairment.
Change in baseline perception of cognitive impairment at 12 months
Change in Sleep-related Impairment as measured by the PROMIS Sleep related Impairment Short Form 8a
Time Frame: Change in baseline perception of cognitive impairment at 12 months
An 8-item instrument measuring indicators of sleep-related impairment with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater sleep-related impairment.
Change in baseline perception of cognitive impairment at 12 months
Change in the PROMIS Brief Sexual Function & Satisfaction Measure Male
Time Frame: Change in baseline perception of sexual function and satisfaction at 12 months among male participants
An 11-item instrument measuring indicators of male sexual function and satisfaction with a recall period over the last 30 days. Responses are provided on various 2- to 10-point scales across 10 domains: interest in sexual activity, orgasm ability, orgasm satisfaction, oral discomfort, oral dryness, satisfaction with sex life, erectile function. For each item on the instrument a higher score indicates more of the concept being described.
Change in baseline perception of sexual function and satisfaction at 12 months among male participants
Change in the PROMIS Brief Sexual Function & Satisfaction Measure Female
Time Frame: Change in baseline perception of sexual function and satisfaction at 12 months among female participants
A 14-item instrument measuring sexual function and satisfaction for women with a recall period over the last 30 days. Responses are provided on various 2- to 10-point scales across 7 domains: interest in sexual activity, lubrication for sexual activity, orgasm ability, orgasm pleasure, oral discomfort, oral dryness, satisfaction with sex life, vaginal discomfort, vulvar discomfort-clitoral, vulvar discomfort-labial. For each item on the instrument a higher score indicates more of the concept being described.
Change in baseline perception of sexual function and satisfaction at 12 months among female participants
Change in The Comprehensive Score for Financial Toxicity (COST)
Time Frame: Change in baseline perception of financial toxicity at 12 months
An 11-item instrument measuring the financial toxicity of cancer treatment utilizing a five-point ordinal scale ranging from (0- Not at all) to (4- Very much).
Change in baseline perception of financial toxicity at 12 months
Change in Economic Strain and Resilience in Cancer (ENRICh)
Time Frame: Change in baseline perception of financial toxicity at 12 months
An 16-item instrument measuring the financial toxicity of cancer treatment. The first 15 items are rated on an 11-point scale ranging from 0 (lowest financial toxicity burden) to 10 (most severe financial toxicity burden). A final item asks individuals to rank their overall financial situation at the time of the survey compared to prior to their cancer diagnosis, using a 5-point response ranging from much better to much worse.
Change in baseline perception of financial toxicity at 12 months
Change in symptom burden as measured by the Edmonton Symptom Assessment System-Revised (ESAS-R)
Time Frame: Change in baseline perception of symptom burden at 12 months
A 10-item instrument measuring the presence of commonly observed symptoms in individuals with a cancer diagnosis (9 specific items and 1 allowing entry of other problems). Responses for a recall period of the last 24 hours are recorded on an 11-point scale ranging from 0 (none/not present) to 10 (worst possible).
Change in baseline perception of symptom burden at 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in medication adherence for individuals taking maintenance therapies
Time Frame: Change in baseline perception of medication adherence at 12 months
A three-item instrument used to measure medication adherence, asking about difficulty taking medications on time, average days per week with one dose missed, and the last time a dose was missed. Responses are on differing scales, with higher values meaning better adherence.
Change in baseline perception of medication adherence at 12 months
Physical Activity
Time Frame: From date of enrollment up to 12 months
Step count will be collected via Fitbits provided to study participants
From date of enrollment up to 12 months
Physical Activity
Time Frame: From date of enrollment up to 12 months
Minutes of physical activity will be collected via Fitbits provided to study participants
From date of enrollment up to 12 months
Digital Engagement
Time Frame: From date of enrollment up to 12 months
Frequency, types and duration of engagement with the digital health coaching platform
From date of enrollment up to 12 months
Gut Microbiota
Time Frame: From date of enrollment to 6 months
16s analysis of fecal microbiome specimens self-collected by participants
From date of enrollment to 6 months
Health Care Utilization
Time Frame: From date of enrollment to 12 months
ER visits and unplanned hospitalizations as documented in the electronic health record
From date of enrollment to 12 months
Dietary Intake as measured by the Diet History Questionnaire (DHQ) III
Time Frame: Within 2 weeks of microbiome collection at enrollment and month 6
An electronic food diary assessment capturing dietary intake over the last 24 hours. The number of items
Within 2 weeks of microbiome collection at enrollment and month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pack Health

Collaborators

M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
The University of Texas Health Science Center, Houston
GlaxoSmithKline
National Institute of Nursing Research (NINR)
Dana-Farber Cancer Institute
Gilead Sciences
University of Florida
Ohio State University Comprehensive Cancer Center
University of Nebraska
Daiichi Sankyo

Investigators

  • Principal Investigator: Marilyn Hammer, PhD, Dana-Farber Cancer Institute
  • Principal Investigator: Alexi Wright, MD, Dana-Farber Cancer Institute
  • Principal Investigator: Elizabeth Arthur, PhD, The Ohio State University Wexner Medical Center
  • Principal Investigator: Jessica Krok-Schoen, PhD, The Ohio State University Wexner Medical Center
  • Principal Investigator: Robin Lally, PhD, The University of Nebraska
  • Principal Investigator: Rachael Schmidt, DNP, Nebraska Medicine
  • Principal Investigator: Anneliese Gonzalez, MD, UTHealth Houston McGovern Medical School
  • Principal Investigator: Kristen Fessele, PhD, Memorial Sloan Kettering Cancer Center
  • Principal Investigator: Debra E Lyon, PhD, University of Florida College of Nursing
  • Principal Investigator: Kathrin Milbury, PhD, The University of Texas MD Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 23, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

April 14, 2022

First Submitted That Met QC Criteria

April 21, 2022

First Posted (Actual)

April 27, 2022

Study Record Updates

Last Update Posted (Estimated)

December 11, 2024

Last Update Submitted That Met QC Criteria

December 6, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 202101
  • ZIANR000020-06 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Digital Health Coaching Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe